On Tuesday, Immunome Inc (NASDAQ: IMNM) opened lower -3.38% from the last session, before settling in for the closing price of $12.44. Price fluctuations for IMNM have ranged from $7.48 to $30.96 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 18.60% at the time writing. With a float of $51.19 million, this company’s outstanding shares have now reached $60.42 million.
The extent of productivity of a business whose workforce counts for 55 workers is very important to gauge. In terms of profitability, gross margin is 88.22%, operating margin of -3134.4%, and the pretax margin is -3014.59%.
Immunome Inc (IMNM) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Immunome Inc is 17.98%, while institutional ownership is 81.84%. The most recent insider transaction that took place on Nov 21 ’24, was worth 630,263. In this transaction President and CEO of this company bought 66,057 shares at a rate of $9.54, taking the stock ownership to the 485,693 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO bought 33,943 for $9.78, making the entire transaction worth $331,918. This insider now owns 519,636 shares in total.
Immunome Inc (IMNM) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.60% per share during the next fiscal year.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Check out the current performance indicators for Immunome Inc (IMNM). In the past quarter, the stock posted a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 74.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.12, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach -3.00 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
The latest stats from [Immunome Inc, IMNM] show that its last 5-days average volume of 0.65 million was inferior to 0.78 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 8.44%. Additionally, its Average True Range was 0.96.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 38.90%, which indicates a significant increase from 11.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.27% in the past 14 days, which was higher than the 74.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.19, while its 200-day Moving Average is $15.05. Now, the first resistance to watch is $12.47. This is followed by the second major resistance level at $12.93. The third major resistance level sits at $13.31. If the price goes on to break the first support level at $11.63, it is likely to go to the next support level at $11.25. The third support level lies at $10.79 if the price breaches the second support level.
Immunome Inc (NASDAQ: IMNM) Key Stats
There are currently 62,417K shares outstanding in the company with a market cap of 750.25 million. Presently, the company’s annual sales total 14,020 K according to its annual income of -106,810 K. Last quarter, the company’s sales amounted to 2,910 K and its income totaled -47,100 K.
